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Renal medullary cancer is a rare malignancy almost exclusively seen in young patients of African ethnicity. These patients often
present with the cardinal symptoms of hematuria, flank pain, and an abdominal mass, and this malignancy has been associated
with patients carrying sickle cell trait. It is estimated that 300 million people worldwide carry sickle cell trait, and the presence of
hematuria in these patients should be treated as a harbinger of a possible malignancy. Notably, this tumor mostly develops on the
right side of the body. Patients often present with it at an advanced stage and the prognosis is poor. Therefore, a high index of sus-
picion in a patient of African descent presenting with a right sided abdominal mass and hematuria may assist in an early diagnosis.
Currentchemotherapyoptionsareverylimited,andearlydetectionmayprovideachanceforsurgicalresection.Itmayalsoprovide
a bigger time frame for the initiation of novel chemotherapy regimens in patients who fail current chemotherapy regimens.
1. Introduction
Renal medullary cancer was described in 1995 by Davis
et al. in a case series of 34 patients collected over 22 years.
He reported a highly aggressive neoplasm with microscopic
morphology of sickled erythrocytes in the tissue. Sickle cell
trait was linked to all the cases except one patient who
had hemoglobin SC disease [1]. To date, approximately 120
cases have been described in the medical literature, with
only one report of its association with sickle cell disease
[2]. Most patients present with the triad commonly seen
in renal carcinoma, that is, gross hematuria, flank pain,
and a palpable abdominal mass. Nearly 75% of the tumor
m a s s e sa r er e p o r t e dt ob eo nt h er i g h ts i d e[ 3, 4]. Evidence
of metastatic disease at the time of presentation is not
uncommon. CT scan and MRI are imaging modalities of
choice as there are instances of failure to detect a distinct
renal mass using ultrasound [4]. Radiologically, the tumor
tends to be poorly circumscribed, hypodense, and markedly
infiltrative often with areas of internal necrosis, hemorrhage,
and heterogeneity. Regional lymphadenopathy is common at
presentation, as is distant metastatic disease to liver, lung,
pleura, or omentum [5]. The relative low prevalence of this
malignancy in patients with sickle cell disease is notable. It is
possible that the sickle cell disease itself exerts a protective
effect due to sickling of cells in the tumor vasculature and
auto-infarcting it before the tumor grows further. However,
there are no epidemiological studies to support this hypoth-
esis. Here, we report the presentation and clinical course of
a patient with sickle cell trait who presented with hematuria
and was found to have renal medullary cancer.
2. Case Description
A33-year-oldAfricanAmericangentleman,whoimmigrated
to the United States from Cameroon 8 years ago presented






(b) H&E staining showing pleomorphic cells with large vesicular nuclei with variable cytoplasm.
and nonproductive cough for duration of 1 week. He had a
history of hypertension well controlled with amlodipine. He
had been a life-long nonsmoker and denied use of any illicit
drugs. He also denied any fever or chills or upper respiratory
symptoms, oliguria or pedal edema. Review of other systems
was unremarkable. On examination, he was noted to be in
mild respiratory distress but was able to converse in full
sentences. He was afebrile; blood pressure was 133/83mmHg
and heart rate was 91/minute, breathing at a rate of 24/minute
with an oxygen saturation of 96% on ambient air. He did not
have palpable cervical, axillary, or epitrochlear lymph nodes.
His chest auscultation was significant for decreased breath
sounds in the right base with dullness to percussion, and
the left lung had clear vesicular breath sounds. His abdomen
was nondistended, without any organomegaly. Initial routine
laboratory investigation was significant for a normal white
count with differentials, normal hemoglobin, and platelets,
blood urea nitrogen of 11mg/dL, and serum creatinine of
1.2mg/dL.Theurineanalysiswasremarkableforoccultblood
but had no protein or glucose. Chest X-ray (CXR) revealed
a large right pleural effusion, a small left pleural effusion,
and multifocal bilateral pulmonary opacities. This prompted
acomputedtomography(CT)scanofthechestandabdomen,
which confirmed a large loculated right pleural effusion,
small layering left pleural effusion, and multiple pleural
based nodular enhancements, the largest of which measured
9.5 × 1.6cm. There were innumerable pulmonary nodules
t h r o u g h o u tt h el e ftl u n ga n dv i s u a l i z e dp o r t i o no ft h er i g h t
lung. The left hilar lymph nodes were significantly enlarged.
There was also a 5.8 × 5.2 × 5cm irregular left lower pole
low attenuation cystic renal mass, with adjacent 2.6 × 2.1cm
leftpara-aorticlymphadenopathyand1×1cmexophyticcyst
from the lower pole of the right kidney (Figures 1(a) and
1(b)). The ultrasound of the scrotum revealed a 3 × 2.2 ×
2.9cm fluid collection superior to the right testis suggestive
of spermatocele. Serum tumor markers like Alpha Feto-
Protein and serum human Chorionic Gonadotropin were
unremarkable. A therapeutic thoracentesis on the right chest
was done, and 1.8L of serosanguinous fluid was removed.
Pleural fluid analysis revealed a white blood cell count ofCase Reports in Oncological Medicine 3
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Figure 3: ((a), (b), (c), and (d)) Immunohistochemistry showing positive staining for CK 7, calretinin, MOC31, and CK 20 (focal).
1175/mm
3, predominantly polymorphic neutrophils (70%),
with lactate dehydrogenase of 271U/L, glucose of 63mg/dL
and total protein of 5g/dL, suggestive of an exudate. Cultures
for bacterial, fungal, and acid fast bacilli were negative.
Cytology was reported to be negative for malignant cells.
Video-assisted thoracoscopic surgery (VATS) was requested
to obtain definitive diagnosis. Inspection of the pleural
cavity after evacuation of 1L of bloody fluid during VATS
revealed multiple deposits in both the parietal and visceral
pleura, which were biopsied. Histopathological examination
of the pleural biopsies revealed infiltrating tumor growth
demonstrating reticular, solid, microcystic, adenoid cystic
patterns and desmoplastic stroma. The cells were pleomor-
phic with large vesicular nuclei with variable cytoplasm
(Figures 2(a) and 2(b)). Immunohistochemistry was positive
for cytokeratins: CK7, CK19, CK20 (focal staining), CK903,
epithelial glycoprotein-2 (MOC31), epithelial cell adhesion
molecule (BerEp), epithelial membrane antigen (EMA),
mucin 1 (MUC1), vimentin, and calretinin (Figures 3(a),
3(b), 3(c),a n d3(d)). They were negative for thyroid tran-
scription factor-1 (TTF1), napsin; caudal type homeobox
transcription factor 2 (CDX2), carcinoembryonic antigen
(CEA); and human epidermal growth factor receptor 2
(Her2/neu), O-linked sialoglycoprotein (MW 40kDa) [D2-
40],transformation-relatedprotein63(p63),cytokeratins5/6
(CK5/6),placentalalkalinephosphatase(PLAP),AFP,CD30,
and alpha-methylacyl CoA racemase (p504S). These features
wereindicativeofpoorlydifferentiatedadenocarcinomaofan
unknown primary. Given the African American ethnicity of
the patient, renal mass and metastatic poorly differentiated
adenocarcinoma, a diagnosis of metastatic renal medullary
cancer was considered. This diagnosis was further supported
when hemoglobin electrophoresis results were found to have
a sickle cell trait (HbS-40.4% and HbA-55.6%). His post-
operativeperiodwasotherwiseuneventful.Unfortunately,he
was lost to further follow up.
3. Discussion
Sickle cell trait (HbAS) is characterized by the inheritance
of an abnormal sickle cell B1-globin gene along with nor-
mal hemoglobin gene (HbA) resulting in alpha2/betaS1beta1
hemoglobinconfiguration[6].Largelyconsideredasabenign
carrier state usually with none of the symptoms of sickle cell
disease, it offers relative protection against severe malaria.
Current cumulative evidence is convincing for associations
with hematuria, renal papillary necrosis, hyposthenuria,
splenic infarction, exertional rhabdomyolysis, and exercise-
related sudden death [7]. The prevalence of sickle cell trait
is approximately 8–10 percent in African Americans, and
it is as high as 25–30 percent in certain areas of western
Africa [8, 9]. Individuals with sickle cell trait do not appear
to have increased mortality rate as compared to the general
population.
Compared to all the benign manifestations of sickle cell
trait described above, renal medullary carcinoma is a rare
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patients with sickle cell trait [1]. The tumor is hypothesized
to arise from the epithelium of the distal collecting ducts
and grows in an infiltrative pattern, invading the renal
sinuses. The genetic changes related to these tumor types
a r es t i l ll a r g e l yu n k n o w n .P r e v i o u sr e p o r t so fi m m u n o h i s -
tochemical studies suggested the association of expressions
of tumor protein 53 (TP53), vascular endothelial growth
factor (VEGF), or hypoxia inducible factor (HIF) with the
tumorigenesis [10]. Increased amplification of Abelson gene
and absence of SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin subfamily B member 1
protein may also be involved in the pathogenesis of renal
medullary carcinoma [11, 12]. In gross appearance, the tumor
tends to be lobulated, firm, and poorly circumscribed. On
histopathological examination, it reveals a cohesive group of
cellswithvacuolatedcytoplasm,displacedorindentednuclei,
andprominentnucleoli.BoththeDavisetal.andSwartzetal.
series demonstrated reticular pattern, cytoplasmic inclusions
resembling rhabdoid tumor, and a high incidence of tumor
hemorrhage [1, 10].
Management options for renal medullary carcinoma
include radical nephrectomy, chemotherapy, and palliative
radiation therapy. The median survival is 15 months [7].
Simpson et al. and Swartz el al. reported the longest survivals
for 46 weeks and 15 months, respectively [10, 11]. Motzer et
al. reported a case of complete response to bortezomib at 27
months of follow up [13]. A recent report of rearrangements
in anaplastic lymphoma kinase (ALK) receptor kinase as a
possible mechanism for the tumorigenesis in this carcinoma
opens the possibility of use of direct and indirect ALK
inhibitors in the management of these patients [14]. Early
detectionmayhelpdecidethepossibilityofsurgicalresection
and the initiation of chemotherapy regimens. Failure of these
interventions may pave the path for possible participation in
chemotherapy trials with novel agents and help enhance our
understanding of the management of this rare malignancy.
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